Clinical Trial Update: A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin [Phase 3]

View source ↗

Summary

A Phase 3 trial investigating AMR101 (icosapent ethyl) for reducing cardiovascular events in high-risk patients with hypertriglyceridemia on statin therapy has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Diseases

Drugs mentioned

• AMR101 (icosapent ethyl) (icosapent ethyl)

Snippet

Sponsor: Amarin Pharma Inc. | Conditions: Cardiovascular Diseases | Phase 3 | Status: COMPLETED | Results posted: 2022-04-14